Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Treasury Shares: 2013-2024

Historic Treasury Shares for Ptc Therapeutics (PTCT) over the last 12 years, with Dec 2024 value amounting to $3.5 million.

  • Ptc Therapeutics' Treasury Shares rose 5.35% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 5.35%. This contributed to the annual value of $3.5 million for FY2024, which is 23.07% up from last year.
  • Latest data reveals that Ptc Therapeutics reported Treasury Shares of $3.5 million as of FY2024, which was up 23.07% from $2.9 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Treasury Shares ranged from a high of $3.5 million in FY2024 and a low of $982,058 during FY2020.
  • Its 3-year average for Treasury Shares is $3.0 million, with a median of $2.9 million in 2023.
  • Data for Ptc Therapeutics' Treasury Shares shows a peak YoY soared of 65.57% (in 2022) over the last 5 years.
  • Ptc Therapeutics' Treasury Shares (Yearly) stood at $982,058 in 2020, then soared by 54.76% to $1.5 million in 2021, then surged by 65.57% to $2.5 million in 2022, then rose by 13.91% to $2.9 million in 2023, then grew by 23.07% to $3.5 million in 2024.